57 related articles for article (PubMed ID: 38726002)
1. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of geriatric nutritional risk index in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Eur J Surg Oncol; 2024 Jun; 50(6):108323. PubMed ID: 38603867
[TBL] [Abstract][Full Text] [Related]
3. Gastric cancer immune microenvironment score predicts neoadjuvant chemotherapy efficacy and prognosis.
Zhao S; Liu Y; Ding L; Zhang C; Ye J; Sun K; Song W; Cai S; He Y; Peng J; Xu J
J Pathol Clin Res; 2024 May; 10(3):e12378. PubMed ID: 38778559
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for esophageal cancer: Where are we now and where can we go.
Shoji Y; Koyanagi K; Kanamori K; Tajima K; Ogimi M; Ninomiya Y; Yamamoto M; Kazuno A; Nabeshima K; Nishi T; Mori M
World J Gastroenterol; 2024 May; 30(19):2496-2501. PubMed ID: 38817664
[TBL] [Abstract][Full Text] [Related]
5. Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study.
Hu M; Li X; Lin H; Lu B; Wang Q; Tong L; Li H; Che N; Hung S; Han Y; Shi K; Li C; Zhang H; Liu Z; Zhang T
Int J Surg; 2024 Apr; 110(4):2275-2287. PubMed ID: 38265431
[TBL] [Abstract][Full Text] [Related]
6. The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma.
Wang Z; Zhao Y; Wo Y; Peng Y; Hu W; Wu Z; Liu P; Shang Y; Liu C; Chen X; Huang K; Chen Y; Hong H; Li F; Sun Y
Cancer Lett; 2024 May; 593():216951. PubMed ID: 38734159
[TBL] [Abstract][Full Text] [Related]
7. ASO Author Reflections: Enhancing Treatment Outcomes in Unresectable Esophageal Squamous Cell Carcinoma Through Immunochemotherapy.
Huang S; Wang S; Gao Z; Qiao G
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38802710
[No Abstract] [Full Text] [Related]
8. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
[TBL] [Abstract][Full Text] [Related]
10. A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Front Immunol; 2023; 14():1217967. PubMed ID: 37954582
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
[TBL] [Abstract][Full Text] [Related]
12. Deciphering Treg cell roles in esophageal squamous cell carcinoma: a comprehensive prognostic and immunotherapeutic analysis.
Zhang P; Dong S; Sun W; Zhong W; Xiong J; Gong X; Li J; Lin H; Zhuang Y
Front Mol Biosci; 2023; 10():1277530. PubMed ID: 37842637
[No Abstract] [Full Text] [Related]
13. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Ann Surg Oncol; 2024 Jan; 31(1):272-283. PubMed ID: 37838648
[TBL] [Abstract][Full Text] [Related]
14. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.
Ausejo-Mauleon I; Labiano S; de la Nava D; Laspidea V; Zalacain M; Marrodán L; García-Moure M; González-Huarriz M; Hervás-Corpión I; Dhandapani L; Vicent S; Collantes M; Peñuelas I; Becher OJ; Filbin MG; Jiang L; Labelle J; de Biagi-Junior CAO; Nazarian J; Laternser S; Phoenix TN; van der Lugt J; Kranendonk M; Hoogendijk R; Mueller S; De Andrea C; Anderson AC; Guruceaga E; Koschmann C; Yadav VN; Gállego Pérez-Larraya J; Patiño-García A; Pastor F; Alonso MM
Cancer Cell; 2023 Nov; 41(11):1911-1926.e8. PubMed ID: 37802053
[TBL] [Abstract][Full Text] [Related]
15. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
[TBL] [Abstract][Full Text] [Related]
16. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L; Li Y; Tan J; Xu L; Li Y
J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
[TBL] [Abstract][Full Text] [Related]
17. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.
Chen P; Wang L; Yang X; Feng J
Biomol Biomed; 2024 Jan; 24(1):159-169. PubMed ID: 37597214
[TBL] [Abstract][Full Text] [Related]
18. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors.
Sauer N; Janicka N; Szlasa W; Skinderowicz B; Kołodzińska K; Dwernicka W; Oślizło M; Kulbacka J; Novickij V; Karłowicz-Bodalska K
Cancer Immunol Immunother; 2023 Nov; 72(11):3405-3425. PubMed ID: 37567938
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]